# Senicapoc and Perampanel for Newly Diagnosed Glioblastoma

> **NCT07284069** · EARLY_PHASE1 · RECRUITING · sponsor: **Aarhus University Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** senicapoc
- **DRUG:** Perampanel

## Key facts

- **NCT ID:** NCT07284069
- **Lead sponsor:** Aarhus University Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07284069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07284069, "Senicapoc and Perampanel for Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07284069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*